US. UK price target £9.Joking but.. it feels that way with this stock sometimes.. |
US or UK listing? |
Berenberg cuts target price to 1600p from 1820p |
Now going down so it should show thumbs down ? |
Every year I wonder why they don't do tomorrow the other way round??
Good luck all 👍🏻 |
United States stock markets will be closed on Thursday, Nov. 28 and will close early on Friday, Nov. 29 in observance of the Thanksgiving holiday. |
Took advantage of the dip this afternoon and decided to increase my holding a bit. I can't see this not doing well and the dividend is good |
And there's more ......
GSK plc (LSE/NYSE: GSK) today announced that the European Medicine Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended for use a single-vial, fully liquid presentation of Menveo (Meningococcal Group A, C, W-135 and Y conjugate vaccine, MenACWY vaccine) to help protect against invasive meningococcal disease (IMD) caused by bacterial groups A, C, W, and Y. |
I assume we are talking about the US listing share price |
I preferred the 2610p ..........;0) |
Bernstein cuts target price to 2355p from 2610p |
That's what I thought , but no impact on today |
Nice late trades |
Blenrep combinations accepted for review by the US FDA for the treatment of relapsed/refractory multiple myeloma
· Regulatory submission supported by phase III head-to-head DREAMM-7 and DREAMM-8 trials showing statistically significant efficacy, including overall survival in DREAMM-7
· If approved, Blenrep (belantamab mafodotin) in combinations with BorDex (BVd) and PomDex (BPd) could redefine multiple myeloma treatment at or after first relapse
· Sixth major regulatory filing acceptance this year for belantamab mafodotin combinations in this indication |
No rush await the inevitable dip. |
More good news ....
Arexvy approval expanded to adults aged 50-59 at increased risk of severe RSV disease in Japan
· First RSV vaccine approved in Japan to help protect 50-59 year olds at increased risk due to certain underlying health conditions
· RSV infections can exacerbate these underlying health conditions and lead to severe outcomes, such as pneumonia, hospitalisation and death.
· 35 countries, including the US, have expanded approval for GSK's RSV vaccine in this at increased risk population |
Have added more just now.
It is my opinion that the reason the economy is in such dire straits is primarily because our esteemed fund managers are a complete and utter bunch of nimrods.
This is a buy but wtfdIk |
1820 to 1300 wow!At what point is the doom and gloom priced in? Obviously sentiment is low but as we all should know.... things can quickly turn. I am holding firm and just topped up earlier this week. There are always 2 sides to a coin |
Target 600 pence ! |
Not a good sector to be invested in at the moment.Another class action initiated. This time against J&J.Never ending gravy train for greedy lawyers. |
Next stop 12 quid. |
Yep I didn't bet the house on it. Just topped up as this level seems attractive and good support. Oversold imo but who knows. Buy and hold. |
This is GSK; he only has coal for us.. |
Supermarky
Must be close to the lows surely.
Tempted but I'm going to sit tight until the new year personally..
unless there are some serious gyrations over the incoming December low liquidity period. |
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
Hot Features
Premium
